RHÖN-KLINIKUM Aktiengesellschaft
ISIN: DE0007042301
WKN: 704230
07 May 2026 08:42PM

EQS-News: RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026

RHÖN-KLINIKUM Aktiengesellschaft · ISIN: DE0007042301 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2323556

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Quarter Results/Miscellaneous
RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026

07.05.2026 / 20:42 CET/CEST
The issuer is solely responsible for the content of this announcement.


CORPORATE NEWS

First quarter of 2026

RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026
 

  • Group optimises outpatient and inpatient care structures
  • Number of patients treated increased by 7.4 %, while the reported consolidated revenue is at EUR 436.1 million
  • Current financial year affected by upcoming reforms

Bad Neustadt, 7 May 2026 – RHÖN-KLINIKUM AG entered financial year 2026 with stable business performance. Consolidated revenue of EUR 436.1 million was slightly above the prior year's figure (Q1 2025: EUR 414.7 million), while EBITDA amounted to EUR 30.2 million (Q1 2025: EUR 22.6 million). Net income totalled EUR 13.1 million (Q1 2025: EUR 7.3 million). From January to March, the Group's clinics and medical centres treated 258,027 patients on an inpatient and outpatient basis, an increase of 7.4 % (Q1 2025: 240,137).

The hospital sites of the company continue to see dynamic growth. In addition to the major investments in state-of-the-art medical technology planned at all hospital sites in 2026, we are further expanding our medical and therapeutic care for patients throughout the Group.

In the first quarter of 2026, the operating business of Ortho Centrum Saale MVZ GmbH was integrated into the Group and its results included in the consolidated financial statements. The company, with six doctor’s practices in the specialist fields of orthopaedics, trauma surgery, surgery, sports medicine, sports trauma medicine and neurosurgery, was acquired to strengthen the RHÖN-Campus concept in Bad Neustadt as well as growth prospects in the clinical and outpatient sector in the region of Rhön-Grabfeld.

Outlook for 2026

For the coming financial year, we expect revenues of EUR 1.7 billion within
a range of plus or minus 5 %. For earnings before interest, tax and depreciation/amortisation (EBITDA), we expect a level of between
EUR 110 million and EUR 125 million. In addition to the financial performance indicators, we also take account of the non-financial performance indicators
of number of cases and cost weights in the management of the company and expect these to show a moderate improvement over the previous year.

The current financial year is expected to be significantly affected by legislative procedures and its corresponding substantial uncertainties. In particular, the Hospital Reform Adjustment Act (KHAG), which entered into force on 15 April 2026, as well as the implications of the Statutory Health Insurance Financial Stabilization Act (GKV-Finanzstabilisierungsgesetz), while aiming to further strengthen quality and efficiency within the healthcare system, simultaneously increase financial pressure on hospitals in the short term.

The Group’s forecast is therefore subject to considerable uncertainties. The cumulative impact of ongoing regulatory interventions, the implementation of the German hospital reform, and potential further adjustments by the legislature can currently not be reliably estimated. In addition to these developments global crises and economic pressures, which manifest – among other developments – in price increases, supply restrictions, and volatile operating conditions.

Considering these aspects, it will be decisive whether further adjustments to the ongoing reforms and supporting measures will be implemented to enable hospitals providing economically sustainable and high-quality patient care in the future.

Dr. Stefan Stranz, Member of the Executive Board of RHÖN-KLINIKUM AG: “Reliable medical care requires economically stable hospitals. Particularly against the backdrop of current reforms, it will be crucial whether financing and regulatory frameworks continue to enable hospitals to fulfill their mandate providing care in a sustainable manner.”

Dr. Gunther K. Weiß, Member of the Executive Board RHÖN-KLINIKUM AG: “Our business processes are both efficient and flexible. The close and trustworthy collaboration within the ASKLEPIOS Group plays a significant role in these. At the same time, the impact of current reforms and further regulatory interventions remains subject to considerable uncertainty. To permanently ensure high-quality and reliable patient care, hospitals require stable economic and political conditions.”

The Quarterly Statement – Q1 2026 – is published in the Internet.

CONTACT

RHÖN-KLINIKUM AG | Head of Group Finance
Norman Dittes | T. +49 9771 65-12210 | norman.dittes@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Corporate Communications
Heike Ochmann | T. +49 9771 65-12130 | heike.ochmann@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale

 

RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. With Campus Bad Neustadt, Zentralklinik
Bad Berka, Klinikum Frankfurt (Oder) as well as the Giessen and Marburg University Hospitals (UKGM), the company has
five highly specialised maximum- and intermediate-care hospitals. As a modern, diverse and future-oriented company,
RHÖN-KLINIKUM AG is attractive both as an employer and training centre. With over 19,100 employees, the Group offers excellent medical care with a direct tie-in to research and teaching. Each year, over 938,000 patients are treated in the
Group’s hospitals and medical care centres (MVZs) on an outpatient and inpatient basis. RHÖN-KLINIKUM AG is a company
of the ASKLEPIOS Group. www.rhoen-klinikum-ag.com



07.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a. d. Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate BSX
EQS News ID: 2323556

 
End of News EQS News Service

2323556  07.05.2026 CET/CEST

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2020 2021 2022 2023 2024 2025 2026e
Sales1 1.360,16 1.402,01 1.446,09 1.463,98 1.595,62 1.704,72 1.700,00
EBITDA1,2 80,23 101,16 105,65 105,88 110,77 105,94 117,00
EBITDA-Margin3 5,90 7,22 7,31 7,23 6,94 6,22 6,88
EBIT1,4 10,60 30,52 36,11 40,40 48,15 40,94 44,00
EBIT-Margin5 0,78 2,18 2,50 2,76 3,02 2,40 2,59
Net Profit (Loss)1 2,46 30,23 26,94 40,17 45,21 36,28 40,00
Net-Margin6 0,18 2,16 1,86 2,74 2,83 2,13 2,35
Cashflow1,7 113,30 97,50 41,30 109,00 127,60 57,20 85,00
Earnings per share8 0,02 0,42 0,38 0,58 0,65 0,52 0,60
Dividend per share8 0,00 0,00 0,15 0,00 0,10 0,20 0,20
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: KPMG

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Rhön-Klinikum
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
704230 DE0007042301 AG 837,03 Mio € 19.06.1991 Halten 9F2G86FM+GX
* * *
PE 2027e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
18,94 26,94 0,70 24,61 -0,47 14,63 0,49
Dividends
Dividend '2023
in €
Dividend '2024
in €
Dividend '2025e
in €
Div.-Yield '2025e
in %
0,00 0,10 0,20 1,60%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
27.05.2026 07.05.2026 06.08.2026 05.11.2026 26.03.2026
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
-0,79%
12,50 €
ATH 32,12 €
-0,68% +1,12% -1,57% -3,10% +400,00%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2026          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2026 by Gereon Kruse #BGFL